Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy

Dapagliflozin is a selective sodium–glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure with reduced ejection fraction and chronic kidney disease. In all indications, treatment can be initiated in adults with estimated glomerular f...

Descripción completa

Detalles Bibliográficos
Autores: González Clemente, José M., García Castillo, María, Gorgojo Martínez, Juan J., Jiménez, Alberto, Llorente, Ignacio, Matute, Eduardo, Tejera, Cristina, Izarra, Aitziber, Lecube Torelló, Albert
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10459.1/84490
Acceso en línea:https://doi.org/10.1007/s13300-022-01280-6
http://hdl.handle.net/10459.1/84490
Access Level:acceso abierto
Palabra clave:Dapagliflozin
Sodium-glucose transporter 2 inhibitors
Type 2 diabetes mellitus
Cardiovascular diseases
Therapeutic inertia
Heart failure
id ES_dbbd5e49f100b7567f3d53e3b52c18db
oai_identifier_str oai:recercat.cat:10459.1/84490
network_acronym_str ES
network_name_str España
repository_id_str
spelling Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and MacroangiopathyGonzález Clemente, José M.García Castillo, MaríaGorgojo Martínez, Juan J.Jiménez, AlbertoLlorente, IgnacioMatute, EduardoTejera, CristinaIzarra, AitziberLecube Torelló, AlbertDapagliflozinSodium-glucose transporter 2 inhibitorsType 2 diabetes mellitusCardiovascular diseasesTherapeutic inertiaHeart failureDapagliflozin is a selective sodium–glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure with reduced ejection fraction and chronic kidney disease. In all indications, treatment can be initiated in adults with estimated glomerular filtration rate of at least 25 mL/min/1.73 m2. As monotherapy or as an additive therapy, dapagliflozin has been shown to promote better glycaemic control, associated with a reduction in body weight and blood pressure in a wide range of patients. In addition, dapagliflozin has a positive impact on arterial stiffness, helps to control the lipid profile and contributes to a reduced risk of cardiovascular complications. This article reviews the current scientific evidence on the role of dapagliflozin in cardiovascular risk factors including arterial stiffness, cardiovascular disease and heart failure in patients with T2DM, with the aim of helping to translate this evidence into clinical practice. The underuse of SGLT2i in actual clinical practice is also discussed.Springer Nature202220222022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://doi.org/10.1007/s13300-022-01280-6http://hdl.handle.net/10459.1/84490http://hdl.handle.net/10459.1/84490reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a https://doi.org/10.1007/s13300-022-01280-6Diabetes Therapy, 2022, vol. 13, p. 1281-1298.cc-by (c) José M. González Clemente et. al., 2022.info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/oai:recercat.cat:10459.1/844902026-05-29T05:05:01Z
dc.title.none.fl_str_mv Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
title Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
spellingShingle Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
González Clemente, José M.
Dapagliflozin
Sodium-glucose transporter 2 inhibitors
Type 2 diabetes mellitus
Cardiovascular diseases
Therapeutic inertia
Heart failure
title_short Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
title_full Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
title_fullStr Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
title_full_unstemmed Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
title_sort Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
dc.creator.none.fl_str_mv González Clemente, José M.
García Castillo, María
Gorgojo Martínez, Juan J.
Jiménez, Alberto
Llorente, Ignacio
Matute, Eduardo
Tejera, Cristina
Izarra, Aitziber
Lecube Torelló, Albert
author González Clemente, José M.
author_facet González Clemente, José M.
García Castillo, María
Gorgojo Martínez, Juan J.
Jiménez, Alberto
Llorente, Ignacio
Matute, Eduardo
Tejera, Cristina
Izarra, Aitziber
Lecube Torelló, Albert
author_role author
author2 García Castillo, María
Gorgojo Martínez, Juan J.
Jiménez, Alberto
Llorente, Ignacio
Matute, Eduardo
Tejera, Cristina
Izarra, Aitziber
Lecube Torelló, Albert
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Dapagliflozin
Sodium-glucose transporter 2 inhibitors
Type 2 diabetes mellitus
Cardiovascular diseases
Therapeutic inertia
Heart failure
topic Dapagliflozin
Sodium-glucose transporter 2 inhibitors
Type 2 diabetes mellitus
Cardiovascular diseases
Therapeutic inertia
Heart failure
description Dapagliflozin is a selective sodium–glucose cotransporter 2 inhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure with reduced ejection fraction and chronic kidney disease. In all indications, treatment can be initiated in adults with estimated glomerular filtration rate of at least 25 mL/min/1.73 m2. As monotherapy or as an additive therapy, dapagliflozin has been shown to promote better glycaemic control, associated with a reduction in body weight and blood pressure in a wide range of patients. In addition, dapagliflozin has a positive impact on arterial stiffness, helps to control the lipid profile and contributes to a reduced risk of cardiovascular complications. This article reviews the current scientific evidence on the role of dapagliflozin in cardiovascular risk factors including arterial stiffness, cardiovascular disease and heart failure in patients with T2DM, with the aim of helping to translate this evidence into clinical practice. The underuse of SGLT2i in actual clinical practice is also discussed.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.1007/s13300-022-01280-6
http://hdl.handle.net/10459.1/84490
http://hdl.handle.net/10459.1/84490
url https://doi.org/10.1007/s13300-022-01280-6
http://hdl.handle.net/10459.1/84490
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a https://doi.org/10.1007/s13300-022-01280-6
Diabetes Therapy, 2022, vol. 13, p. 1281-1298.
dc.rights.none.fl_str_mv cc-by (c) José M. González Clemente et. al., 2022.
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
rights_invalid_str_mv cc-by (c) José M. González Clemente et. al., 2022.
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421703588741120
score 15,81155

Similares en LA Referencia